Keyphrases
Pancreatic Ductal Adenocarcinoma
51%
Pancreatic Cancer
39%
Pembrolizumab
34%
Metastatic Pancreatic Ductal Adenocarcinoma
32%
Overall Survival
30%
Confidence Interval
30%
Pancreatic Neuroendocrine Tumors (pNETs)
28%
Resectable Pancreatic Cancer
27%
Irinotecan
24%
Previously Treated
22%
Microsatellite Instability-high (MSI-H)
22%
Mismatch Repair
22%
Tumor
21%
Stereotactic Body Radiation Therapy
21%
Deficient Mismatch Repair (dMMR)
18%
Metastatic Pancreatic Adenocarcinoma
17%
Single Institution
17%
Clinical Outcomes
17%
Neoadjuvant
17%
Gemcitabine
17%
Chemoradiation
17%
Phase II Study
17%
Median Overall Survival
16%
Chemotherapy
16%
Pancreatic Adenocarcinoma
16%
Survival Outcomes
15%
Chemotherapy Alone
14%
Progression-free Survival
14%
Disease-free Survival
13%
Cisplatin
13%
Borderline Resectable
13%
Induction Chemotherapy
12%
Health-related Quality of Life
12%
Non-colorectal
11%
Multiagent Chemotherapy
11%
Hazard Ratio
11%
Upfront Chemotherapy
11%
Neoadjuvant Chemotherapy
11%
Microsatellites
11%
Endometrial Cancer
11%
Nal-IRI
10%
Adjuvant Therapy
10%
Objective Response Rate
10%
Colorectal Cancer
10%
Pancreas
9%
Newly Diagnosed
9%
QLQ-C30
9%
Johns Hopkins Hospital
8%
Capecitabine
8%
Metastatic Pancreatic Cancer
8%
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Pancreas Cancer
79%
Neoplasm
44%
Overall Survival
38%
Pembrolizumab
34%
Pancreas Islet Cell Tumor
34%
Stereotactic Body Radiation Therapy
28%
Gemcitabine
26%
Disease
23%
Biological Marker
23%
Progression Free Survival
23%
DNA Mismatch Repair
21%
Surgery
19%
Adverse Event
17%
Immunohistochemistry
17%
Chemoradiotherapy
17%
Chemotherapy Agent
17%
Microsatellite Instability
17%
Malignant Neoplasm
17%
Paclitaxel
15%
Endometrial Cancer
12%
Immunosuppressive Treatment
12%
Quality of Life
11%
Recurrent Disease
11%
Personalized Medicine
11%
Pancreatic Ductal Adenocarcinoma
11%
Arm
11%
Neoadjuvant Chemotherapy
11%
Adjuvant Therapy
10%
Hazard Ratio
9%
Solid Malignant Neoplasm
9%
Stroma
9%
Disease Free Survival
9%
Cyclophosphamide
9%
Monotherapy
8%
Temozolomide
8%
Oncology
8%
Capecitabine
8%
Patient Population
8%
Metastatic Carcinoma
8%
Radiation Therapy
7%
CD8 Antigen
7%
Long Term Survival
7%
Immunotherapy
7%
Induction Chemotherapy
6%
Neutrophil
6%
Cancer Stem Cell
6%
Lymphocyte
6%
Prognostic Factor
6%
Diagnosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
63%
Pancreas Cancer
56%
Chemotherapy
43%
Overall Survival
36%
Neoplasm
31%
Irinotecan
31%
Pembrolizumab
28%
Progression Free Survival
26%
Gemcitabine
24%
Malignant Neoplasm
18%
Capecitabine
16%
Chemoradiation Therapy
16%
Cisplatin
14%
Biological Marker
12%
Disease
12%
Adverse Event
12%
Endometrium Cancer
12%
Immunoreactive Insulin
11%
Paclitaxel
10%
Temozolomide
9%
Monotherapy
7%
Carcinoembryonic Antigen
7%
Fluorouracil
7%
Solid Malignant Neoplasm
7%
Docetaxel
7%
Chemotherapy Agent
6%
Tumor Microenvironment
6%
Neuroendocrine Tumor
5%
N (6,7 Dihydro 6 Oxo 5h dibenz[b,d]azepin 7 Yl) 2,2 Dimethyl N' (2,2,3,3,3 Pentafluoropropyl)propanediamide
5%
Pseudotumor
5%
Antigen
5%
Phase I Trials
5%
Metformin
5%
Rapamycin
5%
Erlotinib
5%
Carcinoma
5%
Brain Tumor
5%
Focal Adhesion Kinase
5%
Metastatic Colorectal Cancer
5%
Colorectal Cancer
5%
Lymph Node Metastasis
5%
Colon Cancer
5%
Cytomegalovirus
5%
Vismodegib
5%
Mitomycin
5%
Guadecitabine
5%
Opportunistic Infection
5%
Fibrosis
5%
Olaparib
5%
Hedgehog
5%